RaiaDrogasil (RADL3) posted adjusted net income of R$ 439 million in 3Q26 (R$ 439.1 million), up 9.2% from 3Q25, with a net margin of 3.3% (down 0.2 percentage point). Excluding the effects of 4Bio, a business that was sold and is treated as discontinued, net income grew 20.1% and the margin rose 0.1 percentage point. The figures are pre-IFRS 16.
Gross revenue totaled R$ 13.2 billion (R$ 13,163 million), growth of 16.0% and an increase of R$ 1.8 billion over 3Q25 (R$ 11,348 million). The Stix effect was +0.4 percentage point and the calendar effect was -0.3 percentage point. Mature-store sales grew 8.4%, 5.6 percentage points above the 2.8% price adjustment set by CMED (Medicines Market Regulation Chamber). Same-store sales rose 10.1%.
Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was R$ 1,023.7 million, up 14.7%, with a margin of 7.8% (-0.1 percentage point). Gross profit reached R$ 3,795.6 million, with a margin of 28.8% (+0.1 percentage point), supported by Stix, lower shrinkage and commercial gains, which offset the present value adjustment (AVP) and the GLP-1 and digital mix. Adjusted EBT (earnings before income tax) advanced 31.0% to R$ 547.6 million, with a margin of 4.2% (+0.5 percentage point). Adjusted financial expenses fell 0.6 percentage point to R$ 174.9 million, due to a lower Selic rate, AVP and the sale of 4Bio. The effective tax rate was 19.8%.
Digital sales reached R$ 3.8 billion (R$ 3,838 million), up 27.2%, with a 29.4% share of retail sales. National market share rose 1.1 percentage point to 19.1%, with gains in all regions. The chain reached 3,770 pharmacies, with 92 openings and 9 closures in the quarter. There were 333 openings over the last 12 months, and the company reiterated its target of 330 to 350 openings in 2026. The base is 53 million active customers and 119 million customer interactions in the quarter, with an NPS of 91.
Free cash flow was R$ 160.2 million and total cash generation was R$ 56.8 million, including 4Bio effects. Adjusted net debt was R$ 2,942.7 million, equivalent to 0.8 times EBITDA, a reduction of 0.3 times. The company will hold RD Saúde Day on December 7 at the RD Saúde Campus in São Paulo.
